



## **EISAI PRODUCT CREATION SYSTEMS (EPCS) UNDERGOES TRANSFORMATION WITH AIM OF FURTHER FOCUSING AND STRENGTHENING PRODUCT CREATION CAPABILITIES**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that the company's research and development organization, Eisai Product Creation Systems (EPCS), has undergone a transformation with the aim of further focusing and strengthening its product creation capabilities. In order to fulfill its sole mission of ensuring that innovative new drugs that meet unmet medical needs are made available to patients as early as possible, EPCS has flexibly implemented organizational changes deemed necessary according to the progress of Eisai's development pipeline. The changes will allow Eisai to better prioritize and define its product creation activities by creating a leaner organizational structure that will more efficiently drive forward high-priority projects, increase focus on next-generation products and investigational compounds, and enhance the pursuit of innovation during development and discovery.

The major changes are as follows:

1. **Function Optimization of Product Creation Units (PCUs) and Strengthening of Chief Clinical Officer (CCLO) Function**

To reflect Eisai's increased focus on key drug discovery areas, EPCS has undergone a shift in its structure. Previously, EPCS had a centralized management model within a single Core Function Unit (CFU) for clinical support functions worldwide. The new model has transferred those management responsibilities to other PCUs/CFUs in order to streamline communications and decision making. Other key clinical support functions such as those for statistical analysis and clinical pharmacology have been placed under the direct jurisdiction of the CCLO in an effort to further improve clinical success rates. The former Scientific & Operational Clinical Support (SOCS) CFU has also been dissolved as part of these changes.

Additionally, in regard to drug discovery in the area of neuroscience at Eisai's EMEA\* Knowledge Centre (EKC) in the United Kingdom, focus on the Open Innovation function, which primarily conducts joint research with University College London, has been increased, while

**[Notes to editors]**

**1. About Eisai Product Creation Systems (EPCS)**

The Eisai Group defines its research and development (R&D) activities as Product Creation in accordance with its mission to ensure that innovative drugs are delivered to patients as early as possible. The Group's R&D organization, Eisai Product Creation Systems (EPCS), combines venture-like productivity and speed with the knowledge resources of a global pharmaceutical company so as to establish a system that shortens development timelines, in turn helping to realize the early creation of innovative new drugs to treat diseases for which sufficient treatment does not yet exist.

EPCS encompasses Production Creation Units (PCUs), Core Function Units (CFUs), and the Product Creation Headquarters. The PCUs, which comprise five units, including units specializing in oncology and neurology, are wholly responsible for conducting the series of processes ranging from discovery of innovative drug candidates through regulatory filing and approval. The CFUs, which will now comprise five units, take full responsibility for obtaining and maintaining a highly competitive edge in preclinical and clinical operations, technology, regulatory affairs and other shared core functions as well as promoting new drug development in cooperation with the PCUs.

Meanwhile, the Product Creation Headquarters are responsible for formulation of product creation structural strategies, corporate portfolio management, and the promotion of product creation activities. Through this EPCS system, the Eisai Group is striving to build an organization comprising autonomous units with clearly defined responsibilities and which are specialized in each disease or technology area so as to encourage a sense of